5402

Eiko LifeSciences Stock Price

Symbol: BSE:540204Market Cap: ₹708.8mCategory: Materials

540204 Share Price Performance

Community Fair Values

    Recent 540204 News & Updates

    No updates

    Eiko LifeSciences Limited Key Details

    ₹376.6m

    Revenue

    ₹326.6m

    Cost of Revenue

    ₹50.0m

    Gross Profit

    ₹29.0m

    Other Expenses

    ₹21.1m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    1.64
    Gross Margin
    13.28%
    Net Profit Margin
    5.59%
    Debt/Equity Ratio
    4.8%

    Eiko LifeSciences Limited Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About 540204

    Founded
    1977
    Employees
    3
    CEO
    Umesh More
    WebsiteView website
    eikolifesciences.com

    Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals. Its products are used in pharmaceuticals, agrochemicals, aroma chemicals, electronic chemicals, etc. In addition, the company is involved in processing, formulating, producing, buying, selling, and exporting of specialty and fine chemicals. The company was formerly known as Narendra Investments (Delhi) Limited and changed its name to Eiko LifeSciences Limited in June 2021. Eiko LifeSciences Limited was incorporated in 1977 and is based in Thane, India.

    Indian Market Performance

    • 7 Days: -1.6%
    • 3 Months: 5.3%
    • 1 Year: -5.8%
    • Year to Date: -0.5%
    Over the last 7 days, the market has dropped 1.6%, driven by a pullback of 2.1% in the Financials sector. As for last year, the market is also down 5.8%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
    Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
    Continue reading